EA200970839A1 - ЗАМЕЩЁННЫЕ ФЕНОКСИ АМИНОТИАЗОЛОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ РОДСТВЕННОГО ЭСТРОГЕНОВОМУ РЕЦЕПТОРУ РЕЦЕПТОРА-α - Google Patents

ЗАМЕЩЁННЫЕ ФЕНОКСИ АМИНОТИАЗОЛОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ РОДСТВЕННОГО ЭСТРОГЕНОВОМУ РЕЦЕПТОРУ РЕЦЕПТОРА-α

Info

Publication number
EA200970839A1
EA200970839A1 EA200970839A EA200970839A EA200970839A1 EA 200970839 A1 EA200970839 A1 EA 200970839A1 EA 200970839 A EA200970839 A EA 200970839A EA 200970839 A EA200970839 A EA 200970839A EA 200970839 A1 EA200970839 A1 EA 200970839A1
Authority
EA
Eurasian Patent Office
Prior art keywords
arthritis
cartilage
disease
chronic
receptor
Prior art date
Application number
EA200970839A
Other languages
English (en)
Other versions
EA016887B1 (ru
Inventor
Майкл Гаул
Александер Ким
Лили Ли Сирл
Дионисиос Рентзеперис
Жилль К. Биньян
Original Assignee
Янссен Фармацевтика Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39530136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200970839(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика Н.В. filed Critical Янссен Фармацевтика Н.В.
Publication of EA200970839A1 publication Critical patent/EA200970839A1/ru
Publication of EA016887B1 publication Critical patent/EA016887B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Настоящее изобретение относится к соединениям формулы (I)способам получения этих соединений, их композициям, промежуточным соединениям и производным для лечения состояний, включающих, но не ограниченных ими, анкилозирующий спондилит, артериосклероз, артрит (такой как ревматоидный артрит, инфекционный артрит, детский артрит, псориатический артрит, реактивный артрит), связанные с костями заболевания (включая заболевания, связанные с остеогенезом), рак молочной железы (включая виды, нечувствительные к антиэстрогеновой терапии), сердечно-сосудистые нарушения, связанное с хрящом заболевание (такое как повреждение/потеря хряща, дегенерация хряща, и таковые, связанные с формированием хряща), хондродисплазию, хондросаркому, хроническое повреждение спины, хронический бронхит, хроническое воспалительное заболевание дыхательных путей, хроническое обструктивное заболевание легких, диабет, нарушения гомеостаза энергии, подагру, псевдоподагру, липидные нарушения, метаболический синдром, множественную миелому, ожирение, остеоартрит, несовершенный остеогенез, остеолитический костный метастаз, остеомаляцию, остеопороз, болезнь Педжета, периодонтальное заболевание, ревматическую полимиалгию, синдром Рейтера, туннельный синдром, гипергликемию, повышенный уровень глюкозы в крови и резистентность к инсулину.
EA200970839A 2007-03-07 2008-03-06 ЗАМЕЩЁННЫЕ ФЕНОКСИАМИНОТИАЗОЛОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ РОДСТВЕННОГО ЭСТРОГЕНОВОМУ РЕЦЕПТОРУ РЕЦЕПТОРА-α EA016887B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89346407P 2007-03-07 2007-03-07
PCT/US2008/056029 WO2008109737A1 (en) 2007-03-07 2008-03-06 Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators

Publications (2)

Publication Number Publication Date
EA200970839A1 true EA200970839A1 (ru) 2010-04-30
EA016887B1 EA016887B1 (ru) 2012-08-30

Family

ID=39530136

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970839A EA016887B1 (ru) 2007-03-07 2008-03-06 ЗАМЕЩЁННЫЕ ФЕНОКСИАМИНОТИАЗОЛОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ РОДСТВЕННОГО ЭСТРОГЕНОВОМУ РЕЦЕПТОРУ РЕЦЕПТОРА-α

Country Status (17)

Country Link
US (1) US8580832B2 (ru)
EP (1) EP2134698A1 (ru)
JP (1) JP2010520308A (ru)
KR (1) KR20090128454A (ru)
CN (1) CN101679327A (ru)
AR (1) AR065657A1 (ru)
AU (1) AU2008222755B2 (ru)
BR (1) BRPI0808776A2 (ru)
CA (1) CA2680212A1 (ru)
CL (1) CL2008000667A1 (ru)
EA (1) EA016887B1 (ru)
IL (1) IL200759A0 (ru)
MX (1) MX2009009520A (ru)
NZ (1) NZ579417A (ru)
TW (1) TW200902506A (ru)
UA (1) UA98484C2 (ru)
WO (1) WO2008109737A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
CA2697399C (en) 2007-09-14 2016-01-19 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones
MX2010002537A (es) 2007-09-14 2010-08-10 Ortho Mcneil Janssen Pharm 4-fenil-1h-piridin-2-onas 1,3-disubstituidas.
NZ584145A (en) 2007-09-14 2012-03-30 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-[1,4'] bipyridinyl-2'-ones
EP2220083B1 (en) 2007-11-14 2017-07-19 Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
MX2011003691A (es) 2008-10-16 2011-09-06 Ortho Mcneil Janssen Pharm Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico.
ES2401691T3 (es) 2008-11-28 2013-04-23 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
NZ596053A (en) 2009-05-12 2013-05-31 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US20130040951A9 (en) * 2009-08-04 2013-02-14 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for cancer
WO2011019558A1 (en) * 2009-08-11 2011-02-17 Janssen Pharmaceutica Nv Methods to measure dissociation rates for ligands that form reversible covalent bonds
US8187871B2 (en) * 2009-08-11 2012-05-29 Janssen Pharmaceutica N.V. Co-crystallization of ERR-α with a ligand that forms a reversible covalent bond
CA2784753A1 (en) * 2009-12-18 2011-06-23 Janssen Pharmaceutica Nv Substituted aminothiazolone indazoles as estrogen related receptor-.alpha. modulators
US8426604B2 (en) 2010-02-17 2013-04-23 Janssen Pharmaceutica Nv Aminothiazolones as estrogen related receptor-alpha modulators
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
WO2012062750A1 (en) 2010-11-08 2012-05-18 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
WO2013018929A1 (en) 2011-08-04 2013-02-07 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
NZ700872A (en) 2012-03-26 2016-09-30 Nippon Chemiphar Co Prophylactic or therapeutic agent for giant cell tumors occurring in bone and soft tissue or for chondrosarcoma
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
JP6527822B2 (ja) 2013-09-25 2019-06-05 日本ケミファ株式会社 骨・軟部に発生する巨細胞性腫瘍、軟骨肉腫または骨肉腫の予防、治療または転移の予防のための薬剤、動脈塞栓術用局所注入剤、および、人工骨
KR20220049612A (ko) 2014-01-21 2022-04-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
ES2748633T3 (es) 2014-01-21 2020-03-17 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
CN113939288A (zh) * 2019-03-28 2022-01-14 伊赛恩特制药公司 Mas相关g蛋白受体x4的调节剂及相关产物和方法
CA3144891A1 (en) * 2019-07-04 2021-01-07 Lead Pharma Holding B.V. Estrogen-related receptor alpha (err.alpha.) modulators
CN112538038B (zh) * 2019-09-20 2022-05-20 暨南大学 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用
KR20220066822A (ko) 2020-11-16 2022-05-24 경북대학교 산학협력단 골 질환 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037842A (en) 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
JP2001072592A (ja) * 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
JP2003530437A (ja) * 2000-04-13 2003-10-14 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ Ａβ４２低下物質
DE10131899A1 (de) 2001-07-04 2003-02-27 Boehringer Ingelheim Pharma In vitro-Screening-Assay für gamma-Secretase
EP1398029A1 (en) 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
WO2006004555A1 (en) 2004-06-30 2006-01-12 Paysetter Pte Ltd System and method for facilitating transfer of physical money and/or credit
MX2007000606A (es) * 2004-07-14 2007-06-25 Johnson & Johnson Arilidenos para el tratamiento de enfermedades mediadas por receptor alfa relacionado con estrogeno.
JP4931824B2 (ja) * 2004-10-22 2012-05-16 エグゼリクシス， インコーポレイテッド 薬学的組成物

Also Published As

Publication number Publication date
TW200902506A (en) 2009-01-16
EA016887B1 (ru) 2012-08-30
NZ579417A (en) 2012-02-24
MX2009009520A (es) 2009-11-18
AU2008222755B2 (en) 2013-05-02
AR065657A1 (es) 2009-06-24
US8580832B2 (en) 2013-11-12
JP2010520308A (ja) 2010-06-10
EP2134698A1 (en) 2009-12-23
BRPI0808776A2 (pt) 2014-08-19
UA98484C2 (ru) 2012-05-25
IL200759A0 (en) 2010-05-17
CN101679327A (zh) 2010-03-24
WO2008109737A1 (en) 2008-09-12
CL2008000667A1 (es) 2008-11-03
KR20090128454A (ko) 2009-12-15
CA2680212A1 (en) 2008-09-12
US20080221179A1 (en) 2008-09-11
AU2008222755A1 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
EA200970839A1 (ru) ЗАМЕЩЁННЫЕ ФЕНОКСИ АМИНОТИАЗОЛОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ РОДСТВЕННОГО ЭСТРОГЕНОВОМУ РЕЦЕПТОРУ РЕЦЕПТОРА-α
EA200970837A1 (ru) ЗАМЕЩЁННЫЕ ФЕНОКСИТИАЗОЛИДИНДИОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ α-РЕЦЕПТОРА ЭСТРОГЕНА
EA200970838A1 (ru) ЗАМЕЩЕННЫЕ ФЕНОКСИПРОИЗВОДНЫЕ N-АЛКИЛИРОВАННЫЕ ТИАЗОЛИДИНДИОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ ЭСТРОГЕН-РОДСТВЕННЫХ РЕЦЕПТОРОВ α
TW201144303A (en) Aminothiazolones as estrogen related receptor-α modulators
AR081221A1 (es) Anticuerpos anti gdf8 humano
JP2010520308A5 (ru)
JP2010520306A5 (ru)
JP2018535967A5 (ru)
MX2012009528A (es) Aminotiazolonas como moduladores de receptores alfa relacionados con el estrógeno.
MX2009001534A (es) Preparacion de (r,r)-fenoterol y analogos de (r,r)- o (r,s)-fenoterol y su uso en el tratamiento de insuficiencia cardiaca congestiva.
MX2021001752A (es) Compuestos de pirrolo-dipiridina.
WO2010141249A3 (en) Generation, characterization and uses thereof of anti-notch3 antibodies
CY1117453T1 (el) Νεες ενωσεις τροποποιησης toy fxr (nr1h4)
TN2010000125A1 (en) Substituted biphenyl gpr40 modulators
BRPI0508791A (pt) composto, composição farmacêutica, uso do composto, método para elevar o hdl em um indivìduo, método para o tratamento de diabetes do tipo 2, resistência à insulina diminuìda ou redução da pressão do sangue em um indivìduo, método para diminuir o ldlc em um indivìduo, método para deslocar o tamanho de partìcula de ldl denso pequeno a ldl normal em um indivìduo, método para o tratamento de doenças ateroscleróticas incluindo doença vascular, doença das coronárias do coração, doença cerebrovascular e doença de vaso periférico em um indivìduo, método para o tratamento de doenças inflamatórias, incluindo a artrite reumatoide, a asma, a osteodistrofia e doença autoimune em um individuo, metodo de tratamento de uma doença ou condição medida por hppar-delta, método de modulação de uma função de receptor ativada por proliferador de peroxisoma (ppar), e método de tratamento de uma doença ou uma condição
JP2010535206A5 (ru)
EA200200921A1 (ru) Полуамиды малоновой кислоты и их производные в качестве лигандов тиреоидных рецепторов
JP2009506167A5 (ru)
CY1118044T1 (el) Παρασκευασμα συνδυασμου με ανταγωνιστη και κορτικοστεροειδες
JP2016525130A5 (ru)
EA201990479A1 (ru) Сульфонамиды в качестве агонистов gpr40 и gpr120
JP2012054542A5 (ja) トリアゾール誘導体および複素環化合物
EA201171074A1 (ru) Цитотоксические конъюгаты с соединением, связывающим рецептор нейропептида y
SI2197841T1 (sl) Spojine, ki vsebujejo gvanidin, uporabne kot antagonisti muskarinskih receptorjev
JP2014132900A5 (ru)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU